Akero(AKRO) Prnewswire·2024-10-01 01:37Group 1 - Moore Law, PLLC is investigating potential claims against Akero Therapeutics, Inc. regarding misrepresentations about the patient population in the SYMMETRY study [1] - The investigation highlights that approximately 20% of the tested patients had not confirmed NASH as the cause of their cirrhosis, which is critical for data integrity [1] - Akero's stock price fell by 18.15 per share following disappointing interim data from the Phase 2b SYMMETRY trial [2] Group 2 - In the SYMMETRY trial, only 22% (28mg) and 24% (50mg) of patients on EFX showed at least one stage improvement in fibrosis, with no worsening of NASH, but these results were not statistically significant [2] - The trial faced issues with patient discontinuation, with 12 patients, including 11 from EFX groups, dropping out due to drug-related adverse events [2]